Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Related Keywords

Taiwan ,India ,Hong Kong ,Japan ,Israel ,Massachusetts ,United States ,Tokyo ,Cambridge ,Cambridgeshire ,United Kingdom ,Brazil ,Australia ,Saudi Arabia ,Switzerland ,China ,Russia ,Singapore ,Canada ,South Korea ,Great Britain ,Libby Holman ,Jack Cox ,Chuck Triano ,Christophera Viehbacher ,Haruo Naito ,Tsujim Protofibrils ,Eisai Inc ,Facebook ,Prnewswire Eisai Co Ltd ,Exchange Commission ,Youtube ,Eisai Co Ltd ,Linkedin ,European Union ,Eisai Europe Ltd ,Drug Administration ,Biogen Inc ,Nasdaq ,United Nations Sustainable Development Goals Sdgs ,Public Relations Department ,Communications Department ,Investor Relations Department ,Supplemental Biologics License Application ,Biologics License Application ,Fast Track ,Breakthrough Therapy ,Mild Cognitive Impairment ,Dose Management ,Antithrombotic Medication ,Risk Factors ,Intracerebral Hemorrhage ,Prescribing Information ,Relations Department ,Clinical Dementia Rating Sum ,Corporate Concept ,United Nations Sustainable Development Goals ,Important Targets ,Disease Modifying Approach ,Intj Mol ,Accelerated Approval ,Japan Available ,Early Alzheimer ,New England Journal ,